Outcome after treatment for sebaceous carcinoma: A multicenter study.

Loading...
Thumbnail Image

Embargo End Date

Authors

In 't Veld, EH
Keizer, R
Post, N
Versteeg, J
Verdijk, R
Naus, N
Relyveld, G
Crijns, M
Smith, M
Grünhagen, D
Wakkee, M
Paridaens, D
Zavrakidis, I
Mooyaart, A
van Akkooi, A
Strauss, D
Verhoef, C
Wouters, M
Hayes, A
van Houdt, W

Document Type

Journal Article

Date

2022-03-01

Date Accepted

2021-10-15

Abstract

BACKGROUND: Sebaceous carcinoma (SC) is a rare malignant tumour whereby, comprehensive long-term data are scarce. This study aimed to assess the outcome of patients treated with resection for SC. METHODS: Patients treated at four tertiary centres were included. Cumulative incidence curves were calculated for recurrences. RESULTS: A total of 100 patients (57 males, 57%) were included with 103 SCs. The median age was 72 (range, 15-95) years with a median follow-up of 52 (interquartile range [IQR], 24-93) months. Most SCs were located (peri)ocular (49.5%). Of all SCs, 17 locally recurred (16.5%) with a median time to recurrence of 19 (IQR, 8-29) months. The cumulative incidence probability for recurrence was statistically higher for (peri)ocular tumours (p = 0.005), and for positive resection margins (p = 0.001). Two patients presented with lymph node metastases and additional seven patients (8.7%) developed lymph node metastases during follow-up with a median time to metastases of 8 (IQR, 0.5-28) months. Three patients had concurrent in-transit metastases and one patient also developed liver and bone metastases during follow-up. CONCLUSION: SC is a rare, yet locally aggressive tumour. Positive resection margins and (peri)ocular SCs are more frequently associated with local recurrence. SC infrequently presents with locoregional or distant metastases.

Citation

Journal of surgical oncology, 2022, 125 (4), pp. 730 - 735

Source Title

Publisher

WILEY

ISSN

0022-4790

eISSN

1096-9098
1096-9098

Research Team

Sarcoma and Melanoma Surgery

Notes